By Fitt Insider –
Artificial intelligence is disrupting drug discovery.
The latest: OpenAI and longevity startup Retro Biosciences created an AI model for cellular reprogramming, the act of converting aging cells to younger, healthier versions (aka stem cells).
Optimizing AI-powered protein engineering, the GPT-4b model improves cellular rejuvenation efficiency by 50x.
Long game. Benefiting anti-aging science and his portfolio, OpenAI CEO Sam Altman previously invested $180M into Retro, laying the groundwork for the partnership.
